Ovarian teratoma development after anti-NMDA receptor encephalitis treatment. 2017

Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
Division of Child Neurology, Chiba Children's Hospital, Chiba, Japan. Electronic address: takuoma@hotmail.co.jp.

BACKGROUND Anti-NMDA-R receptor encephalitis occurs predominantly in younger women and is often comorbid with ovarian teratoma, a feature that is often absent in children. Here, we report our experience with two pediatric patients, in whom no tumors were present during treatment for encephalitis, but in whom ovarian teratomas developed without encephalitis relapse after treatment was completed. METHODS Patient 1 was a 14-year-old girl who was diagnosed due to characteristic symptoms and anti-NMDA-R antibody. MRI scanning during treatment revealed no ovarian tumors, but a tumor developed in the right ovary 10months after onset. Another tumor developed in the left ovary 3years after onset, and a mature ovarian teratoma was confirmed after bilateral partial ovariectomy. Patient 2 was an 11-year old girl who was also diagnosed due to characteristic symptoms and anti-NMDA-R antibody. Imaging during treatment revealed no ovarian tumors, but a 2.5-cm tumor mass was found in the left ovary 10months after onset, and a mature ovarian teratoma was confirmed after partial ovariectomy. CONCLUSIONS This case report suggests the need for regular tumor screening after treatment for anti-NMDA receptor encephalitis because of potential subsequent tumor development, even in pediatric patients who initially present with no comorbid tumors. No analysis of relapse risk has yet been reported in cases of tumor development after treatment, and at this point, whether or not resection is needed to prevent relapse remains unclear. However, because teratomas usually grow, have an associated risk of torsion, and can be malignant, tumor removal should be considered.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013724 Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642) Dysembryoma,Teratoid Tumor,Teratoma, Cystic,Teratoma, Mature,Teratoma, Benign,Teratoma, Immature,Teratoma, Malignant,Benign Teratoma,Benign Teratomas,Dysembryomas,Immature Teratoma,Immature Teratomas,Malignant Teratoma,Malignant Teratomas,Teratoid Tumors,Teratomas,Teratomas, Benign,Teratomas, Immature,Teratomas, Malignant,Tumor, Teratoid,Tumors, Teratoid
D060426 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies. Anti-NMDA Receptor Encephalitis,Anti-NMDAR Encephalitis,Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis,Non-paraneoplastic Anti-NMDA Receptor Encephalitis,Non-paraneoplastic Anti-NMDAR Encephalitis,Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis,Paraneoplastic Anti-NMDA Receptor Encephalitis,Paraneoplastic Anti-NMDAR Encephalitis,Anti N Methyl D Aspartate Receptor Encephalitis,Anti NMDA Receptor Encephalitis,Anti NMDAR Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitides,Anti-NMDA Receptor Encephalitides,Anti-NMDAR Encephalitides,Anti-NMDAR Encephalitides, Non-paraneoplastic,Anti-NMDAR Encephalitides, Paraneoplastic,Anti-NMDAR Encephalitis, Non-paraneoplastic,Anti-NMDAR Encephalitis, Paraneoplastic,Encephalitides, Anti-N-Methyl-D-Aspartate Receptor,Encephalitides, Anti-NMDA Receptor,Encephalitides, Anti-NMDAR,Encephalitides, Non-paraneoplastic Anti-NMDAR,Encephalitides, Paraneoplastic Anti-NMDAR,Encephalitis, Anti-N-Methyl-D-Aspartate Receptor,Encephalitis, Anti-NMDA Receptor,Encephalitis, Anti-NMDAR,Encephalitis, Non-paraneoplastic Anti-NMDAR,Encephalitis, Paraneoplastic Anti-NMDAR,Non paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis,Non paraneoplastic Anti NMDA Receptor Encephalitis,Non paraneoplastic Anti NMDAR Encephalitis,Non-paraneoplastic Anti-NMDAR Encephalitides,Paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis,Paraneoplastic Anti NMDA Receptor Encephalitis,Paraneoplastic Anti NMDAR Encephalitis,Paraneoplastic Anti-NMDAR Encephalitides,Receptor Encephalitides, Anti-NMDA,Receptor Encephalitis, Anti-NMDA

Related Publications

Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
May 2011, Revista de neurologia,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
October 2010, Journal of pediatric and adolescent gynecology,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
February 2024, BMJ case reports,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
November 2016, Journal of the Intensive Care Society,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
November 2015, Gynecologic oncology reports,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
September 2016, PM & R : the journal of injury, function, and rehabilitation,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
July 2021, BMJ case reports,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
March 2018, BMJ case reports,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
January 2024, Annals of clinical and translational neurology,
Taku Omata, and Kazuo Kodama, and Yoshimi Watanabe, and Yukiko Iida, and Yoshiaki Furusawa, and Akiko Takashima, and Yukitoshi Takahashi, and Hiroshi Sakuma, and Keiko Tanaka, and Katsunori Fujii, and Naoki Shimojo
August 2022, Journal of pediatric and adolescent gynecology,
Copied contents to your clipboard!